etoposide + cisplatin + carboplatin

chemotherapy-Sichuan University-small cell lung cancer refers to the standard-of-care chemotherapy regimen utilized in clinical trials led by Sichuan University for the treatment of extensive-stage small cell lung cancer (SCLC). This regimen consists of etoposide, a topoisomerase II inhibitor that prevents DNA religation, in combination with a platinum-based agent, either cisplatin or carboplatin, which induces DNA cross-linking. Together, these agents disrupt DNA replication and transcription, leading to cell cycle arrest and apoptosis in rapidly dividing cancer cells. In the specific context of Sichuan University's research (such as trial NCT05186103), this chemotherapy backbone is being evaluated as a first-line treatment in combination with the PD-L1 inhibitor adebrelimab and concurrent low-dose radiotherapy (LDRT) to assess potential synergistic effects in improving patient outcomes.

Other names

EP regimenplatinum-etoposide chemotherapyetoposide + cisplatinetoposide + carboplatinchemotherapy-Sichuan University-small cell lung cancer